From Fundamental Building Blocks to First-in-Class Therapeutics — AANOX Investor Relations

AANOX Ltd (London, UK · Delaware, USA) operates at the intersection of fundamental chemistry (AA · Amino Acids) and the unsolved frontiers of disease (NOX · Night & Oxidative Pathology). We are building the foundational operating substrate for pharmaceutical discovery, CMC formulation, and clinical translation.

The Investment Thesis at a Glance

$1.4T Total Addressable Market — Pharma R&D (~$280B), CMC & manufacturing (~$450B), health systems intelligence (~$670B)
Proprietary Core AI Architecture — Structural Causal Models and do-calculus, not correlational ML
End-to-End Value Chain — Discovery → CMC → Clinical Supply in a single integrated platform
Founded 2026 — Registered in London, United Kingdom; Delaware, USA operations
Open for Investment — Institutional investment & biopharma co-development evaluations active

Why Now: The Market Timing

90% of clinical drug candidates fail — the majority due to insufficient mechanistic understanding, not synthesis problems. The convergence of large-scale genomic datasets, causal inference methodology, and compute availability creates a one-time window to replace correlational AI with true mechanistic reasoning.

Competitive Moat: What Cannot Be Replicated

Causal Architecture — Structural Causal Models require deep domain expertise to specify and validate; not achievable by scaling transformers
GxP-Native Design — FDA 21 CFR Part 11 and EU Annex 11 compliance baked into the storage layer (cryptographic audit trails, ALCOA+ provenance), not bolted on
Full Value Chain Coverage — Competing tools cover one vertical; AANOX covers all five clusters in a single integrated platform
Wet-Lab DMTL Loop — In silico triage of 10,000+ candidates → synthesize only top 10–20 high-confidence molecules → 80% reagent waste reduction

Strategic Growth Vectors

Embedded platform licensing to top-20 global pharma companies
Co-development of proprietary amino acid therapeutic pipeline (AANOX Therapeutics division)
Hospital system precision care contracts (NHS, US health systems)
CRO/CDMO process intelligence licensing
Government & defense biological threat preparedness programs

Founders

Deepak Kakran — Founder & CEO
Kusum Chawla — Co-Founder & Chief Scientific Officer

Request a Private Executive Briefing: hello@aanox.com